StockNews.com Lowers ACADIA Pharmaceuticals (NASDAQ:ACAD) to Hold
StockNews.com Lowers ACADIA Pharmaceuticals (NASDAQ:ACAD) to Hold
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) was downgraded by investment analysts at StockNews.com from a "buy" rating to a "hold" rating in a note issued to investors on Tuesday.
在周二发给投资者的一份报告中,斯托克新闻网的投资分析师将阿卡迪亚制药公司(纳斯达克:ACAD-GET评级)的评级从买入下调至持有。
Several other equities research analysts also recently commented on the company. Jefferies Financial Group downgraded ACADIA Pharmaceuticals from a "buy" rating to an "underperform" rating and dropped their target price for the stock from $25.00 to $10.00 in a report on Tuesday, June 21st. Canaccord Genuity Group dropped their target price on ACADIA Pharmaceuticals from $31.00 to $20.00 in a report on Wednesday, June 22nd. Cantor Fitzgerald lowered their price target on ACADIA Pharmaceuticals from $37.00 to $26.00 and set an "overweight" rating on the stock in a report on Tuesday, June 21st. Cowen lowered their price target on ACADIA Pharmaceuticals from $32.00 to $21.00 and set an "outperform" rating on the stock in a report on Monday, August 8th. Finally, The Goldman Sachs Group lowered their price target on ACADIA Pharmaceuticals from $20.00 to $15.00 and set a "neutral" rating on the stock in a report on Tuesday, August 9th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $22.72.
其他几位股票研究分析师最近也对该公司发表了评论。杰富瑞金融集团在6月21日周二的一份报告中将Acadia PharmPharmticals的评级从买入下调至表现不佳,并将该股的目标价从25.00美元下调至10.00美元。在6月22日星期三的一份报告中,Canaccel Genuity Group将Acadia PharmPharmticals的目标价从31.00美元下调至20.00美元。康托·菲茨杰拉德在6月21日(星期二)的一份报告中将他们对阿卡迪亚制药公司的目标价从37.00美元下调至26.00美元,并对该股设定了“增持”评级。考恩在8月8日周一的一份报告中将Acadia PharmPharmticals的目标价从32.00美元下调至21.00美元,并对该股设定了“跑赢大盘”的评级。最后,高盛夫妇在8月9日(星期二)的一份报告中将阿卡迪亚制药的目标价从20.00美元下调至15.00美元,并将该股的评级定为“中性”。一名分析师对该股的评级为卖出,10名分析师对该股给予持有评级,9名分析师对该股给予买入评级。根据MarketBeat.com的数据,该股的平均评级为持有,平均目标价为22.72美元。
ACADIA Pharmaceuticals Stock Up 3.0 %
阿卡迪亚制药类股上涨3.0%
Shares of ACAD stock opened at $17.91 on Tuesday. The stock has a market cap of $2.90 billion, a price-to-earnings ratio of -14.10 and a beta of 0.67. The business's fifty day moving average is $15.98 and its 200 day moving average is $18.76. ACADIA Pharmaceuticals has a twelve month low of $12.24 and a twelve month high of $28.06.
周二,ACAD的股票开盘报17.91美元。该股市值为29亿美元,市盈率为-14.10倍,贝塔系数为0.67。该业务的50日移动均线切入位为15.98美元,200日移动均线切入位为18.76美元。阿卡迪亚制药公司的12个月低点为12.24美元,12个月高位为28.06美元。
Institutional Trading of ACADIA Pharmaceuticals
阿卡迪亚制药公司的机构交易
Several institutional investors have recently made changes to their positions in the business. Lazard Asset Management LLC grew its position in shares of ACADIA Pharmaceuticals by 19.4% during the fourth quarter. Lazard Asset Management LLC now owns 3,115 shares of the biopharmaceutical company's stock worth $72,000 after purchasing an additional 506 shares in the last quarter. Principal Financial Group Inc. grew its holdings in ACADIA Pharmaceuticals by 2.2% during the 1st quarter. Principal Financial Group Inc. now owns 40,349 shares of the biopharmaceutical company's stock valued at $977,000 after buying an additional 884 shares in the last quarter. Personal CFO Solutions LLC grew its holdings in ACADIA Pharmaceuticals by 6.7% during the 1st quarter. Personal CFO Solutions LLC now owns 15,846 shares of the biopharmaceutical company's stock valued at $384,000 after buying an additional 1,000 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in ACADIA Pharmaceuticals by 8.0% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,927 shares of the biopharmaceutical company's stock valued at $434,000 after buying an additional 1,334 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. grew its holdings in ACADIA Pharmaceuticals by 8.5% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 18,837 shares of the biopharmaceutical company's stock valued at $456,000 after buying an additional 1,478 shares in the last quarter. Hedge funds and other institutional investors own 92.48% of the company's stock.
几家机构投资者最近改变了他们在该业务中的头寸。Lazard Asset Management LLC在第四季度将其在Acadia PharmPharmticals的股票头寸增加了19.4%。Lazard Asset Management LLC现在拥有这家生物制药公司3,115股股票,价值72,000美元,上个季度又购买了506股。第一季度,信安金融集团对阿卡迪亚制药公司的持股增加了2.2%。在上个季度又购买了884股后,信安金融集团现在持有40,349股这家生物制药公司的股票,价值977,000美元。第一季度,Personal CFO Solutions LLC在Acadia PharmPharmticals的持股增加了6.7%。Personal CFO Solutions LLC现在拥有这家生物制药公司15,846股股票,价值384,000美元,上个季度又购买了1,000股。苏黎世广东银行在第一季度增持了8.0%的阿卡迪亚制药股份。Zurcher Kantonalbank苏黎世广东银行现在持有这家生物制药公司17,927股股票,价值434,000美元,上个季度又购买了1,334股。最后,奥本海默资产管理公司在第一季度增持了8.5%的阿卡迪亚制药公司的股份。奥本海默资产管理公司(Oppenheimer Asset Management Inc.)现在持有这家生物制药公司18,837股股票,价值456,000美元,上个季度又购买了1,478股。对冲基金和其他机构投资者持有该公司92.48%的股票。
ACADIA Pharmaceuticals Company Profile
阿卡迪亚制药公司简介
(Get Rating)
(获取评级)
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Acadia制药公司是一家生物制药公司,专注于小分子药物的开发和商业化,以解决中枢神经系统疾病中未得到满足的医疗需求。该公司提供NUPLAZID(匹马色林),用于治疗与帕金森氏病精神病相关的幻觉和妄想。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on ACADIA Pharmaceuticals (ACAD)
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- This Is What To Expect From The Q3 Earnings Reporting Season
- 免费获取StockNews.com关于阿卡迪亚制药公司(ACAD)的研究报告
- 达顿餐厅走低通胀之路
- 这3只股票为何在9月火爆开盘
- 通货膨胀没有差别,但它的影响有差别
- 3只被降级的必备股票放在你的观察名单上
- 这是对第三季度收益报告季节的预期
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得《阿卡迪亚医药日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Acadia制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。